Patents by Inventor Patrice Debre
Patrice Debre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250012799Abstract: The present disclosure relates to a HR1-derived polypeptide comprising 10 or more consecutive amino acids of the polypeptide of SEQ ID NO. 8 as disclosed in the description, or a polypeptide derivative thereof. This disclosure also concerns an immunogenic composition comprising a HR1-derived polypeptide as described herein. It also relates to an immunogenic composition comprising a nucleic acid encoding a HR1-derived polypeptide as described herein. In some preferred embodiments, the said nucleic acid consists of a ribonucleic acid.Type: ApplicationFiled: April 7, 2022Publication date: January 9, 2025Inventors: Patrice DEBRE, Vincent VEILLARD, Christian PRADEYROL
-
Patent number: 10174080Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein Nt consists of a peptide having from 0 to 50 amino acids in length, Ct consists of a peptide having from 0 to 50 amino acids in length, each of X1 to X4 consists of an amino acid residue, wherein: (i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, (i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, (i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, (i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaniType: GrantFiled: September 22, 2017Date of Patent: January 8, 2019Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), INNAVIRVAXInventors: Patrice Debre, Vincent Vieillard
-
Publication number: 20180057535Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID N° 1], wherein Nt consists of a peptide having from 0 to 50 amino acids in length, Ct consists of a peptide having from 0 to 50 amino acids in length, each of X1 to X4 consists of an amino acid residue, wherein: (i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, (i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, (i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, (i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaniType: ApplicationFiled: September 22, 2017Publication date: March 1, 2018Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), INNAVIRVAXInventors: Patrice DEBRE, Vincent VIEILLARD
-
Patent number: 9802983Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein —Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that —three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and —the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined inType: GrantFiled: September 30, 2015Date of Patent: October 31, 2017Assignees: INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MEDICALÉ (INSERM), INNAVIRVAXInventors: Patrice Debre, Vincent Vieillard
-
Publication number: 20170128564Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.Type: ApplicationFiled: November 23, 2016Publication date: May 11, 2017Inventors: Vincent VIEILLARD, Patrice DEBRE
-
Publication number: 20160031943Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein —Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that —three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and —the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined inType: ApplicationFiled: September 30, 2015Publication date: February 4, 2016Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), INNAVIRVAXInventors: Patrice DEBRE, Vincent VIEILLARD
-
Patent number: 9181299Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein—Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that—three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and—the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in itsType: GrantFiled: April 13, 2012Date of Patent: November 10, 2015Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), InnavirvaxInventors: Patrice Debre, Vincent Vieillard
-
Publication number: 20140335119Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.Type: ApplicationFiled: May 23, 2014Publication date: November 13, 2014Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique Hopitaux de ParisInventors: Vincent VIEILLARD, Patrice DEBRE
-
Publication number: 20140037666Abstract: The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S—X1-X2-X3-K—X4-Ct (I) [SEQ ID No 1], wherein—Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that—three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and—the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in itsType: ApplicationFiled: April 13, 2012Publication date: February 6, 2014Applicant: INNAVIRVAXInventors: Patrice Debre, Vincent Vieillard
-
Publication number: 20140024018Abstract: An in vitro method for the prognosis of progression of an HIV-1 infection in a patient infected with an HIV-1 virus, comprising the steps of: a) measuring the level of antibodies directed against the 3S peptide of SEQ ID NO 2 in a sample collected from the said patient, b) comparing the level of anti-3S antibodies measured at step a) with a reference value of anti-3S antibody level that is indicative of the progression of the HIV-1 infection.Type: ApplicationFiled: February 21, 2012Publication date: January 23, 2014Applicants: INNAVIRVAX, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Laurence Meyer, Vincent Viellard, Patrice Debre, Joël Crouzet
-
Patent number: 8372955Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease.Type: GrantFiled: October 29, 2007Date of Patent: February 12, 2013Assignees: Assistance Publique Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Vincent Viellard, Patrice Debre
-
Patent number: 7915221Abstract: The present invention provides a method for the design and/or the selection of agonist or antagonist chemokine variants combining a phage display technology and a screening on living cells expressing the receptor of the corresponding native chemokine. It also provides RANTES variants having agonist properties towards said receptor, and methods for preventing and/or curing viral diseases, as well as clues for preventing and/or curing inflammatory or malignant diseases.Type: GrantFiled: April 2, 2007Date of Patent: March 29, 2011Assignee: Universite Pierre et Marie Curie (Paris VI)Inventors: Guy Gorochov, Oliver Hartley, Karim Dorgham, Patrice Debre, Robin Offord
-
Publication number: 20090136533Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.Type: ApplicationFiled: January 29, 2009Publication date: May 28, 2009Applicants: INSERM (Institut National de la Recherche Medicale), Assistance Publique Hopitaux de ParisInventors: Vincent Vieillard, Patrice Debre
-
Publication number: 20090117110Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease.Type: ApplicationFiled: October 29, 2007Publication date: May 7, 2009Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ( INSERM), ASSISTANCE PUBLIQUE HOPITAUX DE PARISInventors: Vincent Vieillard, Patrice Debre
-
Publication number: 20090075874Abstract: The present invention provides a method for the design and/or the selection of agonist or antagonist chemokine variants combining a phage display technology and a screening on living cells expressing the receptor of the corresponding native chemokine. It also provides RANTES variants having agonist properties towards said receptor, and methods for preventing and/or curing viral diseases, as well as clues for preventing and/or curing inflammatory or malignant diseases.Type: ApplicationFiled: April 2, 2007Publication date: March 19, 2009Inventors: Guy Gorochov, Oliver Hartley, Karim Dorgham, Patrice Debre, Robin Offord
-
Patent number: 7211564Abstract: The present invention provides a method for the design and/or the selection of agonist or antagonist chemokine variants combining a phage display technology and a screening on living cells expressing the receptor of the corresponding native chemokine. It also provides RANTES variants having agonist properties towards said receptor, and methods for preventing and/or curing viral diseases, as well as clues for preventing and/or curing inflammatory or malignant diseases.Type: GrantFiled: March 4, 2004Date of Patent: May 1, 2007Assignees: Universite Pierre et Marie Curie (ParisVI), Universite De GeneveInventors: Guy Gorochov, Oliver Hartley, Karim Dorgham, Patrice Debre, Robin Offord
-
Publication number: 20070092525Abstract: The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.Type: ApplicationFiled: February 7, 2005Publication date: April 26, 2007Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique Hopitaux de ParisInventors: Vincent Vieillard, Patrice Debre
-
Publication number: 20060257318Abstract: The present invention relates to the field of the in vitro diagnosis nosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease.Type: ApplicationFiled: February 6, 2004Publication date: November 16, 2006Applicants: Institut National de la Sante et de la Recherche M, Assistance Publique Hopitaux de ParisInventors: Vincent Vieillard, Patrice Debre
-
Publication number: 20050074463Abstract: The invention concerns treatment of infectious and tumoral pathologies comprising a anti-infective and/or anti-tumoral chemotherapeutic treatment phase inducing resistance mutations and a therapeutic vaccination phase directed against said resistance mutations and the agents used in said treatment More particularly, the invention concerns peptides of 8 to 80 amino acids of the HIV reverse transcriptase sequence and comprising at least a mutation with respect to said wild sequence of said enzyme, mutation induced in response to treatments by nucleoside and non-nucleoside analogues of the HIV reverse transcriptase. The invention also concerns a pharmaceutical composition or vaccine based on said peptides, for inducing an immune response specific of said mutated sequences and for enhancing or prolonging the efficiency of treatments with nucleoside or non-nucleoside analogues of the HIV reverse transcriptase.Type: ApplicationFiled: September 14, 2001Publication date: April 7, 2005Applicant: Universite Pierre et Marie Curie-paris VIInventors: Brigitte Autran, Assia Samri, Patrice Debre, Vincent Calvez, Christine Katlama, Gaby Haas
-
Publication number: 20040258659Abstract: The present invention provides a method for the design and/or the selection of agonist or antagonist chemokine variants combining a phage display technology and a screening on living cells expressing the receptor of the corresponding native chemokine. It also provides RANTES variants having agonist properties towards said receptor, and methods for preventing and/or curing viral diseases, as well as clues for preventing and/or curing inflammatory or malignant diseases.Type: ApplicationFiled: March 4, 2004Publication date: December 23, 2004Inventors: Guy Gorochov, Oliver Hartley, Karim Dorgham, Patrice Debre, Robin Offord